Online Program Home
  My Program
CC = Baltimore Convention Center,    H = Hilton Baltimore
* = applied session       ! = JSM meeting theme

Activity Details

659 * ! Thu, 8/3/2017, 10:30 AM - 12:20 PM CC-342
Clinical Trial Research — Contributed Papers
Biopharmaceutical Section
Chair(s): Brian Wiens, Tobira Therapeutics
10:50 AM A Robust Paradigm of Finding the Maximum Tolerated Dose in Phase I Cancer Clinical Trials Tina Young, Bristol-Myers Squibb ; Dirk Moore, Rutgers School of Public Health ; Yong Lin, Rutgers ; Weichung Joe Shih, Rutgers School of Public Health
11:05 AM Impact of Assessment of Schedule Interval Change on Median Progression-Free Survival Estimate Shuyan Wan, Merck
11:20 AM A Two-Stage, Phase II Clinical Trial Design with Nested Criteria for Early Stopping and Efficacy Michelle DeVeaux, Yale University ; Daniel Zelterman, Yale University ; Michael Kane, Yale University
11:35 AM Program Success Criteria for Drug Approval: P Value vs. Bayesian Posterior Probability Meihua Wang, Merck & Co. ; Frank Liu, Merck & Co. Inc.
11:50 AM Constructing a Synthetic Control Arm from Previous Clinical Trials, with Application to Cancer Trials Steven Schwager, Medidata Solutions ; Michael Elashoff, Medidata Solutions ; Philip Beineke, Medidata Solutions ; Ruthanna Davi, Medidata Solutions
12:05 PM Select a Better Treatment Using Efficacy Safety and Patients' Preference Kao-Tai Tsai
Copyright © American Statistical Association